deformylase

deformylase

a prokaryotic enzyme that removes the formyl group from amino acids, e.g. the methionine coded by the initiation codon AUG.
References in periodicals archive ?
For example some amides are inhibitors of Peptide deformylase and reportedly active against Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli [19, 20].
Margolis, "N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity" Antimicrobial agents and chemotherapy 46, 9 (2002): 2752-2764.
Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and x-ray crystallography validation.
With detailed methods and protocols, contributors address computational strategies, a number of assay methods (for DNA gyrase, topoisomerase IV, bacterial RNA polymerase, bacterial ribosome biogenesis and inhibitors targeting specific translational steps), high-throughput peptide deformylase inhibitor screening, penicillin-binding protein assay methods, methods for assessing the structure and function of cationic antimicrobial peptides, and bacterial efflux pump inhibitors.
A new class of drugs known as peptide deformylase inhibitors could help overcome bacterial resistance to antibiotics, Dr.
The peptide deformylase inhibitors have shown in vitro activity against Chiamydia species, gonococci, spirochetes, and Haemophilus ducreyi.
an Antibiotic Program based on peptide deformylase inhibitors (PDFIs).
The lead compounds in British Biotech's in-house antibiotic programme are peptide deformylase inhibitors in development for respiratory tract and other gram positive infections.
In pre-clinical studies the Antibiotic Program's lead compounds, peptide deformylase (PDF) inhibitors, have shown high potency against gram positive bacteria, in particular drug-resistant strains of Streptococcus pneumoniae.
The Company's preclinical program includes an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.
The Company's preclinical programs include an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.